Dizziness in Sjögren Syndrome: Evaluation and Management
Dizziness in Sjögren syndrome patients requires systematic evaluation for autonomic neuropathy, vestibular dysfunction, and hearing-related causes, as these patients have significantly higher rates of vestibular involvement and autonomic dysfunction compared to the general population.
Understanding the Problem
Dizziness in Sjögren syndrome is not merely a peripheral symptom—it represents potential neurological involvement that affects up to 20% of patients and is frequently underdiagnosed 1, 2. Recent evidence demonstrates that Sjögren patients have significantly elevated rates of vertigo (4.6% vs 3.2% in controls, OR=1.473) 3, and importantly, subclinical vestibular involvement can be detected even when patients are not overtly symptomatic 4.
Algorithmic Evaluation Approach
Step 1: Characterize the Dizziness Type
Determine if the patient experiences:
- True vertigo (spinning sensation) → suggests vestibular involvement
- Presyncope/lightheadedness → suggests autonomic neuropathy with orthostatic hypotension
- Imbalance without spinning → suggests peripheral neuropathy or central involvement
Step 2: Screen for Autonomic Neuropathy
Perform tilt table testing if the patient reports palpitations, presyncope, or lightheadedness with position changes 1. Autonomic neuropathy in Sjögren syndrome can present as the initial manifestation and causes symptomatic orthostatic hypotension requiring specific treatment.
Key clinical indicators:
- Dizziness worsening with standing
- Palpitations
- Extremity paresthesias and pain
- These symptoms may precede classic sicca symptoms
Step 3: Assess Vestibular Function
Order vestibular-evoked myogenic potentials (VEMP) testing and video head impulse test (vHIT) 4. These detect subclinical vestibular involvement:
- Ocular VEMP shows prolonged N1 latency in Sjögren patients
- vHIT reveals reduced vestibulo-ocular reflex gain in posterior and lateral semicircular canals
- These abnormalities occur even without overt symptoms
Step 4: Evaluate Hearing Function
Obtain audiometry as hearing loss occurs in 5.6% of Sjögren patients (vs 3.3% controls, OR=1.724) 3. The association between hearing loss and dizziness is significant—patients presenting with sudden hearing loss and dizziness have poorer prognosis 5.
Screen for:
- Tinnitus (10.1% prevalence in Sjögren vs 6.3% controls)
- Sudden deafness (0.8% vs 0.6%, OR=1.368)
- Progressive hearing loss
Step 5: Rule Out Other Systemic Causes
While the provided pulmonary guidelines 6 focus on respiratory manifestations, they emphasize that Sjögren syndrome requires comprehensive systemic evaluation. Exclude:
- Medication side effects (particularly anticholinergics which should be avoided in Sjögren patients)
- Cardiovascular causes
- Central nervous system involvement (though less common than peripheral)
Management Strategy
For Autonomic Neuropathy with Orthostatic Hypotension:
- Initiate midodrine as first-line therapy 1
- Add beta-blocker if symptoms persist
- Consider IV immunoglobulin (IVIG) for disease modification in severe cases 1
For Vestibular Dysfunction:
- Vestibular rehabilitation therapy should be the primary intervention
- Symptomatic treatment with vestibular suppressants only during acute episodes (avoid chronic use)
- Monitor for progression with repeat VEMP and vHIT testing
For Associated Hearing Loss:
If sudden sensorineural hearing loss occurs with dizziness:
- Offer corticosteroids within 2 weeks of symptom onset 5
- Note: Patients with dizziness at onset of sudden hearing loss have poorer prognosis
- Consider intratympanic steroids if oral contraindicated
Critical Pitfalls to Avoid
Don't dismiss neurological symptoms as "just Sjögren's": Up to 50% of patients report that healthcare providers underestimate their neurological symptoms 2. These manifestations significantly impact quality of life and require active management.
Don't wait for classic sicca symptoms: Neurological manifestations, including dizziness, can be the initial presentation of Sjögren syndrome 1, 7.
Don't use anticholinergic medications: These worsen secretion dryness and should be avoided in all Sjögren patients 6.
Don't assume dizziness is benign: It may herald autonomic dysfunction requiring specific treatment or represent vestibular involvement that benefits from targeted therapy.
Multidisciplinary Collaboration
Coordinate care between rheumatology and neurology 7, 8. The complexity of neuro-Sjögren manifestations requires close collaboration for optimal diagnosis and management. Consider referral to:
- Neurology for autonomic testing and neuropathy evaluation
- Otolaryngology for vestibular testing and hearing assessment
- Rheumatology for systemic disease management optimization
Follow-up Monitoring
- Repeat vestibular testing if symptoms progress
- Monitor for development of other peripheral neuropathy manifestations
- Assess treatment response with validated outcome measures (ESSDAI for systemic activity, ESSPRI for patient-reported symptoms) 9, 10
The evidence strongly supports that dizziness in Sjögren syndrome represents genuine neurological involvement requiring systematic evaluation and targeted treatment rather than symptomatic dismissal.